: Repare Therapeutics started at buy with $48 stock price target at Stifel Nicolaus

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Repare Therapeutics Inc.

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply